# Therapeutic Efficacy of Quercetin Versus Its Encapsulated Nanoparticle on Tongue Squamous Cell Carcinoma Cell Line

> **NCT05456022** · PHASE2 · UNKNOWN · sponsor: **Cairo University** · enrollment: 1000000 (estimated)

## Conditions studied

- Oral Cancer

## Interventions

- **DRUG:** Quercetin 3,3',4',5,6-Pentahydroxyflavone, 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one
- **DRUG:** Quercetin-encapsulated PLGA-PEG nanoparticles (Nano-QUT)
- **DRUG:** Doxorubicin chemotherapeutic drug as a positive control

## Key facts

- **NCT ID:** NCT05456022
- **Lead sponsor:** Cairo University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 1000000 (ESTIMATED)
- **Last updated:** 2022-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05456022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05456022, "Therapeutic Efficacy of Quercetin Versus Its Encapsulated Nanoparticle on Tongue Squamous Cell Carcinoma Cell Line". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05456022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*